Table 1.
Effects of quetiapine fumarate in preclinical models of demyelination/remyelination
| Preclinical model |
|---|
| In vitro |
| ↑Proliferation of NPCs in neurospheres 11 |
| ↑Differentiation of NPCs into OLs 11 |
| ↑Myelination in embryonic neocortical aggregate cell cultures 11 |
| Cuprizone‐induced demyelination |
| ↓Demyelination 11, 18, 19, 20, 21, 22 |
| ↓Loss of mature OLs 11, 18, 19, 20, 21, 22 |
| ↓Activated astrocytes 18 |
| ↓Activated microglia 18 |
| ↓MDA 21 |
| ↑Catalase activity 21 |
| ↑SOD1 activity 18 |
| ↑Myelin restoration (Tx after cuprizone withdrawal) 22 |
| ↑Repopulation of mature OLs (Tx after cuprizone withdrawal) 22 |
| Global cerebral ischemia‐induced demyelination |
| ↓Demyelination 23 |
| ↓Activated astrocytes 23 |
| ↓Loss of mature OLs 23 |
| ↑Repopulation of mature OLs (postoperative Day 40) 23 |
| Experimental autoimmune encephalomyelitis |
| ↓Demyelination 24 |
| ↓Loss of mature OLs 24 |
| ↓Activated astrocytes 24 |
| ↓Activated microglia 24 |
| ↓T‐cell infiltrates 24 |
↑, stimulated by quetiapine; ↓, attenuated by quetiapine; NPC, neural progenitor cell; OL, oligodendrocyte; Tx, treatment; SOD1, copper–zinc superoxide dismutase; MDA, malondialdehyde.